Clemens Muehlan

Idorsia Pharmaceuticals Ltd

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Melvyn Roerdink

assistant professor

NETHERLANDS

View details

Andreas Krause

Chief Scientific Officer

Simulations Plus (United States)

UNITED STATES

View details

Stephan Krähenbühl

University Hospital Basel

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Clemens Muehlan

Research Interests

Explore related searches

Contact this professor

Articles (10)

The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant

Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies

The orexin story and orexin receptor antagonists for the treatment of insomnia

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist

Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects

Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders

The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin

Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration

Collaborators (3)

Melvyn Roerdink

Andreas Krause

Stephan Krähenbühl

Make your next move.